Alerta

CONTINUOUS BLOOD GLUCOSE MEASUREMENT APPARATUS

Resumen de: US20260305987A1

0000 The present disclosure relates to a continuous blood glucose measurement device configured to prevent, in a state where a body attachment unit is inserted in and attached to a human body, an incision portion made by a guide needle from being formed to surround at least a part of a sensing area formed at a sensing member, whereby an incision portion is not formed around the sensing area so as to prevent the incision portion from causing a drop in a blood glucose measurement value and thus enable detection of an accurate blood glucose measurement value from the early stage of operation. Further, the guide needle has a shape not surrounding at least a part of the sensing area, so as to prevent, even without an additional device, the guide needle from forming an incision portion around the sensing area in a human body and thus enhance, by a simple structure, the accuracy of blood glucose measurement.

CHEMICAL ABLATION AND METHOD OF TREATMENT FOR VARIOUS DISEASES

Resumen de: US20260306804A1

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

Using an Online Disturbance Rejection and Anticipation System to Reduce Hyperglycemia

Resumen de: US20260306030A1

0000 Embodiments relate to systems and methods for informing, determining, or controlling insulin dosage. The method involves generating plural disturbance profiles, each disturbance profile being a data representation based on historical patient data pertaining to a deviation from a threshold blood glucose level. The method involves receiving current patient data. The method involves applying a predictive model so that current patient data is compared to a disturbance profile and a probability analysis is used to assess the likelihood of a disturbance profile being an anticipated disturbance profile, the anticipated disturbance profile being a disturbance profile that is determined to match with the current patient data based on the probability analysis. The method involves determining an insulin dose amount based on the anticipated disturbance profile. The method involves outputting a signal representative of the insulin dose amount to a device configured for monitoring, influencing, and/or administering insulin levels in the patient.

METHOD FOR ASSISTING BLOOD GLUCOSE CONTROL OF SUBJECT BY USING COMPUTER SYSTEM, AND COMPUTER SYSTEM

Resumen de: US20260311863A1

0000 According to an embodiment of the present disclosure, there is provided a method for assisting glycemic control of a subject using a computer system, the method including acquiring a self-set goal of the subject; acquiring GA values of the subject; generating a GA value trend using a plurality of the GA values; outputting the GA value trend to the subject; and outputting the self-set goal of the subject to the subject.

METHOD AND APPARATUS FOR PROVIDING DATA PROCESSING AND CONTROL IN MEDICAL COMMUNICATION SYSTEM

Resumen de: US20260305986A1

Methods and apparatus for providing data processing and control for use in a medical communication system are provided. Such methods and apparatus may include determining a glucose value in a bodily fluid based on an estimated glucose temperature related signal and the glucose related signal in the bodily fluid, wherein the glucose temperature related signal may be estimated based on the temperature of the skin or the ambient temperature.

MODULAR PATIENT MONITOR

Resumen de: US20260311579A1

A modular patient monitor provides a multipurpose, scalable solution for various patient monitoring applications. In an embodiment, a modular patient monitor utilizes multiple wavelength optical sensor and/or acoustic sensor technologies to provide blood constituent monitoring and acoustic respiration monitoring (ARM) at its core, including pulse oximetry parameters and additional blood parameter measurements such as carboxyhemoglobin (HbCO) and methemoglobin (HbMet). Expansion modules provide blood pressure BP, blood glucose, ECG, CO2, depth of sedation and cerebral oximetry to name a few. Aspects of the present disclosure also include a transport dock for providing enhanced portability and functionally to handheld monitors. In an embodiment, the transport dock provides one or more docking interfaces for placing monitoring components in communication with other monitoring components. In an embodiment, the transport dock attaches to the modular patient monitor.

METHODS AND SYSTEMS FOR INSULIN DELIVERY AND GLUCOSE MEASUREMENT

Resumen de: US20260306741A1

In an aspect, the present disclosure provides an insulin delivery device configured to be positioned on a body of a subject via a single puncture site in said body of said subject, wherein said insulin delivery device is configured to deliver an insulin or insulin analog formulation to said subject via said single puncture site, wherein said insulin delivery device comprises a sensor configured to measure a glucose concentration in said body of said subject via said single puncture site, and wherein said delivering and said measuring are performed at substantially the same time for a time period of at least 1 hour subsequent to said positioning, while maintaining a sensitivity of said sensor of at least 50% of an initial sensitivity of said sensor.

ADJUSTABLE GLUCOSE SENSOR INITIALIZATION SEQUENCES

Resumen de: EP4817520A2

An example method for initializing a glucose sensor includes executing an initialization sequence for the glucose sensor, wherein the initialization sequence is based on one or more of parameters related to manufacturing the glucose sensor or environmental conditions of the glucose sensor that are present in vivo, and reporting glucose levels in a patient after the initialization sequence.

GRADUAL TRANSITION IN AUTOMATED INSULIN DELIVERY TREATMENT SYSTEM AFTER A TIME CHANGE

Resumen de: WO2025117799A1

Embodiments described herein gradually shift a basal rate pattern for a user in time when the time on an insulin pump is changed and use glucose levels from a CGM sensor to coordinate the shift in the basal pattern with the user's actual glucose response to the changing parameters to safely transition the timing of the basal pattern as quickly as possible.

ADAPTIVE DELIVERY PROFILES FOR AUTOMATED INSULIN DELIVERY TREATMENT SYSTEM

Resumen de: US20250170330A1

0000 Disclosed herein are systems and methods for closed loop and/or partial and/or hybrid closed loop therapy that can provide adaptive personal profiles for when glucose levels are not available and/or unreliable from a continuous glucose monitor (CGM), such as, for example, during a warmup period of the CGM sensor. The profile can include temporary delivery profile such as a CGM warmup profile that is activated specifically for the particular scenario and is designed to minimize the risk of blood glucose fluctuations until the glucose levels are available and reliable, such as when the CGM sensor is warmup up and closed loop therapy based on the sensor can be activated.

COMPRESSION EVENT DETECTION FOR CONTINUOUS GLUCOSE MONITORS

Resumen de: WO2025117512A1

A continuous analyte monitoring system includes first and second analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller Is coupled to the analyte sensors and configured evaluate first samples of outputs of the first analyte sensor and second samples of outputs of the second analyte sensor with respect to one another to determine whether the first samples and the second samples indicate compression of the tissue. If the first samples and the second samples indicate compression of the tissue, compensate for the compression of the tissue with respect to the first samples. The controller may evaluate the machine learning models using a machine learning model or a filter.

DESIGN OF A DEVICE FOR STORING AND LOADING INPUTS NECESSARY FOR THE INJECTION OF A MEDICAMENT

Resumen de: MX2026005362A

The present invention relates to a device for storing and loading inputs necessary for the injection of a medicament among others insulin and is a functional and ergonomic redesign of an insulin injection pen, specifically directed to older adult persons suffering from diabetes or another disease requiring the application of a medicament and presenting articular conditions such as arthritis. This design arises in response to physical limitations facing this group of users by using conventional devices, especially as regards the placement of the needle, the application of force and the precision in handling. The proposal incorporates an assisted mechanism that facilitates insertion of the needle without requiring complex movements, thereby guaranteeing greater comfort, safety and autonomy for the user. In addition, the device has an integrated cooling system that keeps the insulin at a suitable temperature, ensuring the preservation of the drug under optimal conditions. Also included is an automated injection mechanism that allows administering the dose with only pressing a side button of good size, especially designed for hands with reduced mobility. This design seeks not only to improve the use experience, but also contribute significantly to the comfortable and easy handling for people with muscular mobility limitations such as arthritis.

METHOD FOR DETECTING CHRONIC RENAL DISEASE BY MEANS OF A PANEL OF METABOLITE/CREATININE RATIOS AND OF THE SPECTRAL PROFILE BY NON-TARGETED METABOLOMICS OBTAINED BY NUCLEAR MAGNETIC RESONANCE OF HYDROGEN

Resumen de: MX2025002639A

The present invention describes a method for detecting chronic kidney disease (ERC) in samples from subjects with type 2 diabetes (DT2) by metabolic analysis. This method is based on two approaches: a panel of metabolite/creatinine (met/Cr) ratios and a statistical model developed from the spectral profile obtained by hydrogen nuclear magnetic resonance (1H NMR). The method was tested in a cohort of samples from subjects with type 2 diabetes in order to identify renal damage in early stages. The directed metabolomica allows to evaluate the metabolite/creatinine ratio, while the non-targeted metabolomica, based on the 1H NMR spectrum, facilitates initial ERC prediction by statistical analysis and identification of the most affected metabolic pathways. This invention makes it possible to differentiate stadiums from chronic kidney disease and even detect their presence in subjects without obvious symptoms. Its efficacy is supported with a sensitivity of 1,000 and a specificity of 0.895 in the control group, demonstrating its high yield in early identification of the disease. This advancement offers an innovative tool for improving the detection and treatment of CKD in diabetic subjects.

FOOTWEAR LINKED TO AN APPLICATION, FOR ASSISTING IN THE PREVENTION OF ULCERS BY MONITORING PLANTAR PRESSURE

Resumen de: WO2026206158A1

The present invention relates to a device for assisting in the prevention of ulcers, consisting of footwear having interchangeable cells where the plantar pressure is measured in individual areas of the sole of the foot by means of force sensors and sent via Bluetooth to be displayed in an application. The areas at risk of ulceration are thus detected and the cell is removed in order to facilitate plantar distribution, without the risk of developing diabetic foot.

IN VITRO GUT MODEL USING MUCIN-ANALOGS

Resumen de: US20260297531A1

This disclosure relates to an invitro gut model, including an integral layer of intestinal epithelial cells, an artificial mucus atop the integral layer of intestinal epithelial cells, wherein the artificial mucus comprises a silk glycopolymer and optionally a silk polymer lacking sugar substituents, the artificial mucus having a degree of substitution of the silk glycopolymer, a location of substitution of the silk glycopolymer, a concentration of the silk glycopolymer, an overall polymer concentration, an overall silk polymer concentration, an optional concentration of the silk polymer lacking sugar substituents, an optional ratio by weight of the silk glycopolymer and the silk polymer lacking sugar substituents, and/or a silk glycopolymer silk backbone molecular weight is tailored to maintain the integral layer of intestinal epithelial cells for a predetermined length of time, and growth media accessible to the intestinal epithelial cells and tailored to maintain viability of the intestinal epithelial cells.

GROWTH FACTOR SUBSTITUENTS

Resumen de: US20260297529A1

Growth-enhancing peptides and fusion polypeptide are provided. The peptides and fusion polypeptides may be used in cell culture, in particular in the production of cultured meat, as replacement or addition to insulin. There is further provided a cell culture medium comprising at least one of the peptides or fusion polypeptides, and a method for growing cells comprising adding at least one of the peptides or polypeptides to the cell culture medium.

CELLS, ISLETS, AND ORGANOIDS THAT EVADE IMMUNE DETECTION AND AUTOIMMUNITY, METHODS OF PRODUCTION AND USE THEREOF

Resumen de: US20260297530A1

0000 The invention features cells, islet-like cells, pancreatic islets and organoids (e.g., human islet-like organoids or HILOs), as well as cell cultures and methods that are useful for the rapid and reliable generation of cells and organoids, such as pancreatic islets and organoids, that are sustainable in vivo and that evade immune detection, rejection and autoimmunity. The invention also features methods of treating pancreatic diseases, such as type 2 diabetes, and pancreatic cancer, using the cells, islet-like cells, pancreatic islets and organoids (e.g., HILOs) that are designed to modulate the activity of immune cells that would otherwise react against them.

SENSOR FOR ANALYTE MONITORING WITH DRUG-ELUTING CAPABILITIES

Resumen de: US20260294292A1

0000 A sensor (e.g., an analyte sensor) that may be implanted partially or fully within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a housing including one or more indicator portions, a plurality of drug portions on opposite sides of each indicator portion, circuitry within the housing, including a sensing area, analyte indicator material, and a plurality of drug-eluting material in or on the drug portions of the exterior surface of the housing. The drug-eluting material each comprise one or more therapeutic agents that reduce deterioration of the analyte indicator material.

ELECTRICAL METABOLICS

Resumen de: WO2026202693A1

A system, device, and method for treating a diabetic condition are provided. An illustrative device includes: a lead connectable to a signal generator and including a plurality of electrodes, wherein the plurality of electrodes generate a stimulation signal according to an input received from the signal generator and deliver the stimulation signal to one or more anatomical elements of a patient to treat at least one aspect of a diabetic condition based on a closed feedback loop.

MEALTIME DELIVERY OF CORRECTION BOLUSES

Resumen de: US20260295161A1

Disclosed herein are techniques related to delivery of correction boluses. In some embodiments, the techniques involve obtaining data indicative of an ongoing glycemic response to a meal. The data includes glucose concentration measurements evaluated in combination with one or more insulin concentration values. The techniques further include causing delivery of one or more correction doses to at least partially counteract the ongoing glycemic response to the meal. The one or more correction doses are delivered instead of or in addition to a meal bolus delivered for the meal.

SYSTEM AND METHOD OF MODIFYING USER PROFILE IN AUTOMATED INSULIN DELIVERY

Resumen de: US20260295160A1

Disclosed herein are systems and methods for automated insulin delivery that provide for adaptive closed loop control that can modify the stored basal profile used by the closed loop algorithm to better reflect the user's actual needs. Actual delivery rates calculated by the closed loop algorithm can be compared to the user's stored profile. If the differences between the actual delivery rates and the stored profile are statistically significant, the stored profile can be modified.

METHOD FOR STRUCTURING AND CLASSIFICATION OF CONTINUOUS GLUCOSE MONITORING (CGM) PROFILES

Resumen de: US20260294352A1

0000 Embodiment relate to a system for developing a model to classify continuous glucose monitoring (CGM) data. The system includes a processor and computer memory having instructions stored thereon that when executed will cause the processor to determine whether two CGM profiles match based on a similarity of shapes of the two CGM profiles, each CGM profile including a data set of CGM measurements. The processor designates two matching CGM profiles as a CGM profile pair. The processor transforms the CGM profile pair into a motif. The processor labels the motif as a labelled motif based on a clinical characteristic. The processor recursively repeats the determine, designate and transform steps of a CGM profile pairing process until a finite set of motifs is created, which includes the labelled motif as a classified data point. The processor monitor, analyzes, or influences a concentration of glucose levels in a fluid.

CELL PRESERVATION SOLUTION AND CELL PRESERVATION METHOD

Resumen de: US20260297540A1

0000 One aspect of the embodiments relates to a cell preservation solution, comprising: 20 mM~50 mM of sucrose; 20 mM~50 mM of mannitol, 10 mM~50 mM of lactobionic acid, 5 mM~20 mM of glucose, 1 mM~3 mM of adenosine, 1 mM~5 mM of reduced glutathione, 1 mM~2 mM of dextran-40, 10 mM~30 mM of potassium dihydrogen phosphate, 10 mM~30 mM of potassium carbonate, 10 mM~30 mM of potassium chloride, 5 mM~30 mM of sodium chloride, 10 mM~60 mM of sodium hydroxide, 10 mM~60 mM of potassium hydroxide, 0 mM~20 mM of vitamin E, 0 mM~25 mM of 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, and 0%~10% dimethyl sulfoxide. Another aspect of the embodiments relates to a cell preservation method, which uses the cell preservation solutions described in the present application to store cells.

APPLICATOR FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT DEVICE

Resumen de: US20260294290A1

According to the present disclosure, an applicator for a continuous blood glucose measurement device, the applicator being operated by attaching a body attachment unit to the body of a user, the body attachment unit including a sensor member which is inserted into the body of the user in order to measure the blood glucose, comprises: a main case; a plunger to which the body attachment unit is detachably coupled and which is installed in the main case to be movable from a first position to a second position so that the body attachment unit can be discharged to the outer direction of the main case; a needle which is detachably coupled to the body attachment unit so as to be inserted into the body of the user along with the sensor member; and a needle separating unit which separates the needle from the body of the user by moving the needle in the direction opposite to the discharge direction of the plunger, wherein the needle separating unit includes a locking unit which can be assembled with the plunger in the manner of being engaged with one side of the plunger.

PHOTOACOUSTIC MEASUREMENT DEVICE HAVING OPTIMIZED GEOMETRY AND NON-INVASIVE BLOOD GLUCOSE MEASUREMENT DEVICE USING SAME

Nº publicación: WO2026206022A1 01/10/2026

Solicitante:

HME SQUARE INC [KR]
(\uC8FC)\uC5D0\uC774\uCE58\uC5E0\uC774\uC2A4\uD018\uC5B4

Resumen de: WO2026206022A1

The present disclosure provides a photoacoustic measurement method capable of measuring a component of a sample by using photoacoustic waves generated by a laser pulse having a predetermined wavelength. The photoacoustic measurement method may comprise the steps of: oscillating a laser pulse at a predetermined pulse energy and pulse width and causing the laser pulse to be incident toward a photoacoustic generation area within the sample, with an ultrasonic sensor being disposed adjacent to the incident position of the laser pulse in accordance with a predetermined geometry defined by a beam width and incident position of the laser pulse with respect to the sample, the center of the photoacoustic generation area in the sample, and the position of the ultrasonic sensor; detecting, by the ultrasonic sensor, within a predetermined frequency band, photoacoustic waves generated by the laser pulse in the photoacoustic generation area in the sample, and sampling a waveform of the detected photoacoustic waves at a predetermined sampling rate to obtain sampling data; and storing the sampling data.